Wexler, Ryan S.
Balsamo, Wade
Fox, Devon J.
ZuZero, Danielle
Parikshak, Anand
Kwin, Sophia
Ramirez, Jillian
Thompson, Austin R.
Carlson, Hans L.
Kern, Thomas
Mist, Scott D.
Bradley, Ryan
Zwickey, Heather
Pickworth, Courtney K.
Garland, Eric L.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (K12NS130673)
National Center for Complementary and Integrative Health (K24AT011568)
National Center for Complementary and Integrative Health (R90AT008924)
National Center for Complementary and Integrative Health (R01AT011772)
National Institute of Diabetes and Digestive and Kidney Diseases (R25DK130848)
National Institute on Drug Abuse (R01DA056537)
Article History
Received: 11 July 2025
Accepted: 1 February 2026
First Online: 6 March 2026
Declarations
:
: The clinical trial in which this qualitative data was collected was approved by the Institutional Review Board of the National University of Naturopathic Medicine (IRB #: KP112720).
: All participants provided informed consent at their study baseline visit in the parent clinical trial.
: Eric Garland, PhD, LCSW is the Director of UCSD ONEMIND (Optimized Neuroscience-Enhanced Mindfulness Intervention Development). UCSD ONEMIND provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants; however, Dr. Garland has received honoraria and payment for delivering seminars, lectures, and teaching engagements (related to training clinicians in MORE and mindfulness) sponsored by institutions of higher education, government agencies, academic teaching hospitals, and medical centers. Dr. Garland also receives royalties from the sale of books related to MORE. Dr. Garland is also a consultant and licensor to BehaVR, LLC.
: Artificial intelligence was used for editing the manuscript to improve conceptual clarity.